Cardinal Health has extended its drug distribution agreement with CVS Health through June 2032, sending its shares up 3.7% in Thursday trading. The pharmaceutical distributor said it entered into a binding Letter of Intent to extend the existing distribution agreement through June 30, 2032, maintaining the current scope of distribution services. "We value our long-standing partnership with CVS Health and look forward to continuing to bring our best-in-class capabilities together to serve their customers," said Jason Hollar, CEO of Cardinal Health. In connection with the contract renewal, Cardinal Health reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth, or $12.40 to $12.60, and maintained its long-term non-GAAP EPS growth rate guidance of 12% to 14%. The company said further updates may be provided during its upcoming first quarter earnings call on November 5, 2026.
Cardinal Health IncCardinal Health extended its drug distribution agreement with CVS through June 2032, securing continued distribution business.
CVS Health CorpCVS Health is the counterparty extending its drug distribution agreement with Cardinal Health through 2032, maintaining current scope.
